Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Clinical guidance

NICE offers advice on gastro-oesophageal reflux in children

The National Institute for Health and Care Excellence (NICE) has published its first clinical guideline[1] on the management of gastro-oesophageal reflux disease (GORD) in infants and children, which it says constitutes “a health burden for the NHS”.

The guideline, which was developed by the National Collaborating Centre for Women’s and Children’s Health, emphasises the distinction between gastro-oesophageal reflux (GOR) — which NICE says is currently over-treated — and the pathologic variant, GORD.

“It can be difficult to differentiate between ‘normal’ episodes of reflux and more serious GORD, but this new NICE guideline will support medical professionals to make the correct diagnosis,” says Mark Baker, director for the Centre for Clinical Practice at NICE.

GOR affects at least 40% of infants and usually resolves before the age of one year. NICE says that parents and carers should be reassured that GOR does not usually need further investigation or treatment.

“It can be difficult for clinicians to persuade families that distressing and disabling symptoms, for example very frequent and apparently severe vomiting in well, thriving infants, will almost certainly improve with time but can be helped by relatively minor interventions, rather than referral for unnecessary tests or using medications with no proven effect,” says a NICE spokesperson. “This guideline offers clear direction as to when and how families can be re-assured.”

The guideline highlights a number of “red flag” symptoms that may suggest disorders other than GOR, all of which warrant further investigation. These include projectile vomiting, bile-stained vomit, haematemesis and abdominal distension or tenderness.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067588

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.